To understand how an obscure Chinese insurer has been able to fund a $13.5 billion acquisition spree since 2014, look no further than one of its top-selling products, Anbang Longevity Sure Win No. 1.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
